Islet Sciences, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Islet Sciences, Inc.
Tech Transfer Roundup: Voyager Brings Home Pair Of CNS Collaborations
Collaboration with Washington University to co-develop therapies targeting apoliprotein A makes up part of Denali's big August push in Alzheimer's. Kleo gets global rights to two Yale antibody programs and raises Series A cash.
The NASH Pipeline: Replete With Targets And New Compounds
The numerous different targets of investigational drugs for the treatment of NASH suggest the jury is still out on which mechanism of action is most likely to prove effective against the condition. Ireland’s Afimmune is the latest company wanting to advance an investigational drug for the disorder into late-stage clinical studies.
Tobira/Dong-A Partnership Will Add DPP-4 Inhibitor For NASH Combo Therapy
California biotech acquires rights to Suganon, approved for type 2 diabetes in South Korea, while partner Dong-A gets domestic rights to NASH candidate cenicriviroc.
Deals Shaping The Medical Industry, April 2015
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced March 2015.
- Drug Delivery
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
- Gene Therapy, Cell Therapy
- Other Names / Subsidiaries
- DiaKine Therapeutics, Inc.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.